NCT04971226 2026-04-06A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPNovartisPhase 3 Active not recruiting405 enrolled 18 charts 3 FDA
NCT01207492 2026-02-20Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell TumorDana-Farber Cancer InstitutePhase 2 Completed17 enrolled 8 charts
NCT00756509 2026-01-20Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With NilotinibNovartisPhase 4 Completed34 enrolled 11 charts